Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

Pfizer

Status: Completed

Conditions: Invasive Pneumococcal Disease

Treatments: Drug: Pneumococcal 7-valent conjugate vaccine Prevnar

Study type: Observational

Funder types: Industry

Identifiers

NCT00227188

0887-101317

Details and patient eligibility

About

The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)

Enrollment: 408 patients

Sex: All

Ages: Under 5 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.
• Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.

Trial design

408 participants in 1 patient group

1

Description:

Children from 0-5 years of age evaluated for IPD

Treatment:

Drug: Pneumococcal 7-valent conjugate vaccine Prevnar